AZD5305: Clinical Trials

15 trials of AZD5305, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 5 active not recruiting, 2 completed. 10 Phase 1, 6 Phase 2, 3 Phase 3, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 110Active not recruiting 4, Recruiting 4, Completed 2
Phase 26Active not recruiting 3, Recruiting 3
Phase 33Recruiting 2, Active not recruiting 1
Early Phase 11Recruiting 1

Follow AZD5305: new trials by email Literature Review of AZD5305 trials Research Report on AZD5305

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
AZD9750, AZD5305 - Prostate Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca62026-01-272026-10-02
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Phase 2RecruitingSWOG Cancer Research Network9002025-11-062026-03-30
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone - Prostate Cancer
Phase 3RecruitingAstraZeneca7002025-08-062026-10-14
AZD5305 hADME in Patients With Advanced Solid Malignancies
Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose) - Locally Advanced or Metastatic Solid Tumor
Phase 1RecruitingAstraZeneca82025-04-022026-11-12
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Saruparib (AZD5305), Camizestrant, Abemaciclib - Advanced Breast Cancer
Phase 3RecruitingAstraZeneca7882024-08-012026-10-30
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Saruparib, Placebo, Abiraterone Acetate - Metastatic Castration-Sensitive Prostate Cancer
Phase 3Active not recruitingAstraZeneca18982023-11-212026-11-10
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
Saruparib (AZD5305), Darolutamide, No Treatment - Prostate Cancer
Phase 1CompletedAstraZeneca1132023-09-212026-06-30
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Torvutatug samrotecan, Saruparib, Bevacizumab - Ovarian Cancer, Lung Adenocarcinoma
Phase 1 / Phase 2RecruitingAstraZeneca6222023-06-052026-10-05
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
AZD5305, Itraconazole - Advanced Solid Malignancies
Phase 1CompletedAstraZeneca162022-11-072024-06-18
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca1742022-06-022026-08-26
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib) - Breast Cancer, Biliary Tract Carcinoma
Phase 1 / Phase 2RecruitingAstraZeneca4602021-10-182026-10-13
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390 - Non Small Cell Lung Cancer
Phase 1RecruitingUniversity of Leeds2002021-03-172025-12-19
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AZD5305, Paclitaxel, Carboplatin - Ovarian Cancer, Breast Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca7022020-11-122026-09-21
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Cobimetinib, Olaparib, Onvansertib - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Early Phase 1RecruitingOHSU Knight Cancer Institute902019-08-012026-09-04
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab - Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Phase 1Active not recruitingAstraZeneca3582014-10-312026-07-24

Conditions studied

Prostatic Neoplasms (6)  ·  Ovarian Neoplasms (4)  ·  Endometrial Neoplasms (3)  ·  Neoplasms (3)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Pancreatic Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Biliary Tract Neoplasms (1)  ·  Bulbo-Spinal Atrophy, X-Linked (1)  ·  Colorectal Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Small Cell Lung Carcinoma (1)  ·  Stomach Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

AstraZeneca (12)  ·  OHSU Knight Cancer Institute (1)  ·  SWOG Cancer Research Network (1)  ·  University of Leeds (1)

Countries

United Kingdom (12)  ·  United States (12)  ·  Australia (9)  ·  Canada (7)  ·  Japan (7)  ·  South Korea (7)  ·  Spain (7)  ·  China (6)  ·  Italy (6)  ·  Hungary (5)  ·  Poland (5)  ·  Taiwan (5)  ·  France (4)  ·  Germany (4)  ·  Netherlands (4)

Top investigators

Alastair Greystoke, MB ChB, MSc, PhD (1)  ·  Anne C Chiang (1)  ·  Arun Azad, MD (1)  ·  Charles D Lopez (1)  ·  Corinne Faivre-Finn, MD, PhD (1)  ·  Funda Meric-Bernstam, MD (1)  ·  Kim Nguyen Chi, MD (1)  ·  Timothy Yap (1)

Results publications

PMID 34904813, PMID 35929986, PMID 36446040, PMID 39392424, PMID 41917211, PMID 41979035, PMID 42816529

NIH funding

2023 (4), 2014 (1), U10CA180888 (1)